Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 103 results for autologous

  1. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

    HealthTech guidance
    Last updated
    5 August 2025
    View recommendations

    Sections for HTG728

  2. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (HTG356)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

    HealthTech guidance
    Published
    12 November 2014
    View recommendations

    Sections for HTG356

  3. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  4. Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (HTG300)

    Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.

    HealthTech guidance
    Published
    23 January 2013
    View recommendations

    Sections for HTG300

  5. Mosaicplasty for symptomatic articular cartilage defects of the knee (HTG463)

    Evidence-based recommendations on mosaicplasty in people with symptomatic articular cartilage defects of the knee. This involves taking healthy cartilage from the edge of the joint and inserting it into drilled tunnels in the damaged site.

    HealthTech guidance
    Published
    14 March 2018
    View recommendations

    Sections for HTG463

  6. PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)

    NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease

    Medtech innovation briefing
    Published
    13 October 2015

  7. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with...

    Research recommendation
    Published
    5 April 2016

  8. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG162

  9. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

    COVID-19 rapid guideline
    Last updated
    28 September 2023

    Sections for NG164

  10. NICE encourages further data collection, including randomised controlled trials on microstructural scaffold insertion without autologous cell implantation for repairing symptomatic chondral knee defects. Studies should clearly describe patient selection, clinical indications and adjunctive treatments. Outcome measures should include symptom relief, functional ability, long-term outcomes measured by appropriate imaging techniques and patient-reported outcomes.

    randomised controlled trials on microstructural scaffold insertion without autologous cell implantation for repairing symptomatic...

    Research recommendation
    Published
    9 August 2016

  11. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

    Technology appraisal guidance
    Published
    24 September 2025

    Sections for TA1098

  12. NICE encourages further research comparing autologous blood injections (with or without techniques to produce platelet-rich plasma) against established nonsurgical methods for managing tendinopathy. Trials should clearly describe patient selection (including the site of tendinopathy, duration of symptoms and any prior treatments) and document whether a 'dry needling' technique is used. Outcomes should include specific measures of pain, quality of life and function, and whether subsequent surgical intervention is needed.

    IPG438/1 Question NICE encourages further research comparing autologous blood injections (with or without techniques to produce...

    Research recommendation
    Published
    9 June 2015

  13. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA311

  15. Intraoperative blood cell salvage in obstetrics (HTG90)

    Evidence-based recommendations on intraoperative blood cell salvage in obstetrics. This involves filtering and washing shed blood and retransfusing it during or after the procedure.

    HealthTech guidance
    Published
    23 November 2005
    View recommendations

    Sections for HTG90